Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model

Journal of Controlled Release

Volumn 147, Issue 1, 2010, Pages 30-37

  Formiga, Fabio R ^a   Pelacho, Beatriz ^b   Garbayo, Elisa ^a   Abizanda, Gloria ^c   Gavira, Juan J ^b   Simon Yarza, Teresa ^a   Mazo, Manuel ^b   Tamayo, Esther ^a   Jauquicoa, Carlos ^c   Ortiz de Solorzano, Carlos ^c   Prósper, Felipe ^b   Blanco Prieto, Maria J ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Angiogenesis; Controlled release; Myocardial infarction; PLGA microparticles; VEGF

Indexed keywords

ANGIOGENESIS; CONTROLLED RELEASE; MYOCARDIAL INFARCTION; PLGA MICROPARTICLES; VEGF;

RAT CONTROL;

ANIMALS;

ALPHA SMOOTH MUSCLE ACTIN; CAVEOLIN 1; POLYGLACTIN; VASCULOTROPIN 165;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIUM CELL; FEMALE; HEART LEFT VENTRICLE WALL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SUSTAINED DRUG RELEASE;

ANIMALS; CAPILLARIES; CORONARY VESSELS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; LACTIC ACID; MICROSCOPIC ANGIOSCOPY; MYOCARDIAL REPERFUSION INJURY; NEOVASCULARIZATION, PHYSIOLOGIC; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955824571     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.07.097     Document Type: Article

References (52)

1. Chockalingam A., Chalmers J., Lisheng L., Labarthe D., MacMahon S., Martin I., Whitworth J. Prevention of cardiovascular diseases in developing countries: agenda for action (statement from a WHO-ISH Meeting in Beijing, October 1999). J. Hypertens. 2000, 18(12):1705-1708.
2. Bergmann O., Bhardwaj R.D., Bernard S., Zdunek S., Barnabe-Heider F., Walsh S., Zupicich J., Alkass K., Buchholz B.A., Druid H., Jovinge S., Frisen J. Evidence for cardiomyocyte renewal in humans. Science 2009, 324(5923):98-102.
3. Hsieh P.C., Segers V.F., Davis M.E., MacGillivray C., Gannon J., Molkentin J.D., Robbins J., Lee R.T. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat. Med. 2007, 13(8):970-974.
4. Gaffney M.M., Hynes S.O., Barry F., O'Brien T. Cardiovascular gene therapy: current status and therapeutic potential. Br. J. Pharmacol. 2007, 152(2):175-188.
5. Rissanen T.T., Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol. Ther. 2007, 15(7):1233-1247.
6. Passier R., van Laake L.W., Mummery C.L. Stem-cell-based therapy and lessons from the heart. Nature 2008, 453(7193):322-329.
7. Segers V.F., Lee R.T. Stem-cell therapy for cardiac disease. Nature 2008, 451(7181):937-942.
8. Shah P.B., Losordo D.W. Non-viral vectors for gene therapy: clinical trials in cardiovascular disease. Adv. Genet. 2005, 54:339-361.
9. Maulik N., Thirunavukkarasu M. Growth factors and cell therapy in myocardial regeneration. J. Mol. Cell. Cardiol. 2008, 44(2):219-227.
10. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 2008, 103(11):1204-1219.
11. Kinnaird T., Stabile E., Burnett M.S., Lee C.W., Barr S., Fuchs S., Epstein S.E. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ. Res. 2004, 94(5):678-685.
12. Gnecchi M., He H., Liang O.D., Melo L.G., Morello F., Mu H., Noiseux N., Zhang L., Pratt R.E., Ingwall J.S., Dzau V.J. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat. Med. 2005, 11(4):367-368.
13. Perez-Ilzarbe M., Agbulut O., Pelacho B., Ciorba C., San Jose-Eneriz E., Desnos M., Hagege A.A., Aranda P., Andreu E.J., Menasche P., Prosper F. Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. Eur. J. Heart Fail. 2008, 10(11):1065-1072.
14. Pelacho B., Nakamura Y., Zhang J., Ross J., Heremans Y., Nelson-Holte M., Lemke B., Hagenbrock J., Jiang Y., Prosper F., Luttun A., Verfaillie C. Multipotent adult progenitor cell transplantation increases vascularity and improves left ventricular function after myocardial infarction. J. Tissue Eng. Regen. Med. 2007, 1(1):51-59.
15. Yla-Herttuala S., Rissanen T.T., Vajanto I., Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J. Am. Coll. Cardiol. 2007, 49(10):1015-1026.
16. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., Morello F., Mu H., Melo L.G., Pratt R.E., Ingwall J.S., Dzau V.J. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006, 20(6):661-669.
17. Ng Y.S., D'Amore P.A. Therapeutic angiogenesis for cardiovascular disease. Curr. Contr. Trials Cardiovasc. Med. 2001, 2(6):278-285.
18. Hendel R.C., Henry T.D., Rocha-Singh K., Isner J.M., Kereiakes D.J., Giordano F.J., Simons M., Bonow R.O. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000, 101(2):118-121.
19. Hedman M., Hartikainen J., Syvanne M., Stjernvall J., Hedman A., Kivela A., Vanninen E., Mussalo H., Kauppila E., Simula S., Narvanen O., Rantala A., Peuhkurinen K., Nieminen M.S., Laakso M., Yla-Herttuala S. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003, 107(21):2677-2683.
20. Makinen K., Manninen H., Hedman M., Matsi P., Mussalo H., Alhava E., Yla-Herttuala S. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol. Ther. 2002, 6(1):127-133.
21. Rissanen T.T., Markkanen J.E., Arve K., Rutanen J., Kettunen M.I., Vajanto I., Jauhiainen S., Cashion L., Gruchala M., Narvanen O., Taipale P., Kauppinen R.A., Rubanyi G.M., Yla-Herttuala S. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J. 2003, 17(1):100-102.
22. Simons M., Annex B.H., Laham R.J., Kleiman N., Henry T., Dauerman H., Udelson J.E., Gervino E.V., Pike M., Whitehouse M.J., Moon T., Chronos N.A. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002, 105(7):788-793.
23. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., Shah P.K., Willerson J.T., Benza R.L., Berman D.S., Gibson C.M., Bajamonde A., Rundle A.C., Fine J., McCluskey E.R. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003, 107(10):1359-1365.
24. Rajagopalan S., Mohler E.R., Lederman R.J., Mendelsohn F.O., Saucedo J.F., Goldman C.K., Blebea J., Macko J., Kessler P.D., Rasmussen H.S., Annex B.H. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003, 108(16):1933-1938.
25. Kastrup J., Jorgensen E., Ruck A., Tagil K., Glogar D., Ruzyllo W., Botker H.E., Dudek D., Drvota V., Hesse B., Thuesen L., Blomberg P., Gyongyosi M., Sylven C. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J. Am. Coll. Cardiol. 2005, 45(7):982-988.
26. Rutanen J., Rissanen T.T., Markkanen J.E., Gruchala M., Silvennoinen P., Kivela A., Hedman A., Hedman M., Heikura T., Orden M.R., Stacker S.A., Achen M.G., Hartikainen J., Yla-Herttuala S. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004, 109(8):1029-1035.
27. Lee K.Y., Yuk S.H. Polymeric protein delivery systems. Prog. Polym. Sci. 2007, 32:669-697.
28. Lee H., Chung H.J., Park T.G. Perspectives on: local and sustained delivery of angiogenic growth factors. J. Bioact. Compat. Polym. 2007, 22:89-114.
29. Garbayo E., Montero-Menei C.N., Ansorena E., Lanciego J.L., Aymerich M.S., Blanco-Prieto M.J. Effective GDNF brain delivery using microspheres-a promising strategy for Parkinson's disease. J. Control. Release 2009, 135(2):119-126.
30. 14C-vascular endothelial growth factor controlled release microspheres using a rat model. J. Pharm. Pharmacol. 2002, 54:897-905.
31. Mazo M., Planat-Bernard V., Abizanda G., Pelacho B., Leobon B., Gavira J.J., Peñuelas I., Cemborain A., Penicaud L., Laharrague P., Joffre C., Boisson M., Ecay M., Collantes M., Barba J., Casteilla L., Prosper F. Transplantation of adipose derived stromal cells is associated with functional improvement in a rat model of chronic myocardial infarction. Eur. J. Heart Fail. 2008, 10(5):454-462.
32. Carmeliet P., Baes M. Metabolism and therapeutic angiogenesis. N Engl J. Med. 2008, 358(23):2511-2512.
33. Matsusaki M., Sakaguchi H., Serizawa T., Akashi M. Controlled release of vascular endothelial growth factor from alginate hydrogels nano-coated with polyelectrolyte multilayer films. J. Biomater. Sci. Polym. Ed. 2007, 18(6):775-783.
34. Scott R.C., Rosano J.M., Ivanov Z., Wang B., Chong P.L., Issekutz A.C., Crabbe D.L., Kiani M.F. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 2009, 23(10):3361-3367.
35. Chung Y.I., Kim S.K., Lee Y.K., Park S.J., Cho K.O., Yuk S.H., Tae G., Kim Y.H. Efficient revascularization by VEGF administration via heparin-functionalized nanoparticle-fibrin complex. J. Control. Release 2010, 143:282-289.
36. Zhang J., Ding L., Zhao Y., Sun W., Chen B., Lin H., Wang X., Zhang L., Xu B., Dai J. Collagen-targeting vascular endothelial growth factor improves cardiac performance after myocardial infarction. Circulation 2009, 119(13):1776-1784.
37. Davies N., Dobner S., Bezuidenhout D., Schmidt C., Beck M., Zisch A.H., Zilla P. The dosage dependence of VEGF stimulation on scaffold neovascularisation. Biomaterials 2008, 29(26):3531-3538.
38. Scott R.C., Wang B., Nallamothu R., Pattillo C.B., Perez-Liz G., Issekutz A., Del Valle L., Wood G.C., Kiani M.F. Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction. Biotechnol. Bioeng. 2007, 96(4):795-802.
39. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25(4):581-611.
40. Dor Y., Djonov V., Abramovitch R., Itin A., Fishman G.I., Carmeliet P., Goelman G., Keshet E. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 2002, 21(8):1939-1947.
41. Lee R.J., Springer M.L., Blanco-Bose W.E., Shaw R., Ursell P.C., Blau H.M. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000, 102(8):898-901.
42. von Tell D., Armulik A., Betsholtz C. Pericytes and vascular stability. Exp. Cell Res. 2006, 312(5):623-629.
43. Arkonac B.M., Foster L.C., Sibinga N.E., Patterson C., Lai K., Tsai J.C., Lee M.E., Perrella M.A., Haber E. Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells. J. Biol. Chem. 1998, 273(8):4400-4405.
44. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 1995, 146(5):1029-1039.
45. von Degenfeld G., Banfi A., Springer M.L., Wagner R.A., Jacobi J., Ozawa C.R., Merchant M.J., Cooke J.P., Blau H.M. Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. FASEB J. 2006, 20(14):2657-2659.
46. Springer M.L., Ozawa C.R., Banfi A., Kraft P.E., Ip T.K., Brazelton T.R., Blau H.M. Localized arteriole formation directly adjacent to the site of VEGF-induced angiogenesis in muscle. Mol. Ther. 2003, 7(4):441-449.
47. Nagy J.A., Dvorak A.M., Dvorak H.F. VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol. 2007, 2:251-275.
48. Ferrarini M., Arsic N., Recchia F.A., Zentilin L., Zacchigna S., Xu X., Linke A., Giacca M., Hintze T.H. Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ. Res. 2006, 98(7):954-961.
49. Das H., George J.C., Joseph M., Das M., Abdulhameed N., Blitz A., Khan M., Sakthivel R., Mao H.Q., Hoit B.D., Kuppusamy P., Pompili V.J. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model. PLoS ONE 2009, 4(10):e7325.
50. Tambara K., Premaratne G.U., Sakaguchi G., Kanemitsu N., Lin X., Nakajima H., Sakakibara Y., Kimura Y., Yamamoto M., Tabata Y., Ikeda T., Komeda M. Administration of control-released hepatocyte growth factor enhances the efficacy of skeletal myoblast transplantation in rat infarcted hearts by greatly increasing both quantity and quality of the graft. Circulation 2005, 112(9 Suppl):I129-134.
51. Haider H., Jiang S., Idris N.M., Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF- 1alpha/CXCR4 signaling to promote myocardial repair. Circ. Res. 2008, 103(11):1300-1308.
52. Richardson T.P., Peters M.C., Ennett A.B., Mooney D.J. Polymeric system for dual growth factor delivery. Nat. Biotechnol. 2001, 19(11):1029-1034.